her-2/neu peptide vaccine
Vaccineexperimental
Clinical trial activity
10 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 1996 (NCT00003002)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- her-2/neu peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00194714 | Phase 1/Phase 2 (Phase 2) | May 1, 2016 | National Cancer Institute (NCI), University of Washington |
| NCT01729884 | Phase 2 | Dec 1, 2012 | National Cancer Institute (NCI), University of Washington |
| NCT01632332 | Phase 1 | Jul 1, 2012 | Mayo Clinic, Tapimmune Inc. |
| NCT01219907 | Phase 1 | Jun 1, 2012 | National Cancer Institute (NCI), University of Washington |
| NCT01355393 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2011 | National Cancer Institute (NCI), University of Washington |
| NCT00791037 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2008 | National Cancer Institute (NCI), University of Washington |
| NCT00640861 | N/A | Aug 1, 2008 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00068614 | Phase 1 | Jul 1, 2003 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT00005023 | Phase 1 | Mar 1, 1999 | University of Washington |
| NCT00003002 | Phase 1 | Apr 1, 1996 | University of Washington |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 7 | 0 | 3 | 2003 |
| University of Washington | Academic/Hospital | 7 | 7 | 2 | 1996 |
| Mayo Clinic | Academic/Hospital | 2 | 2 | 2 | 2008 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2003 |
| Tapimmune Inc. | For profit | 1 | 0 | 1 | 2012 |
5 organizations
Page 1 / 1